# A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies

> **NCT01100944** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 26 (actual)

## Conditions studied

- Thymoma
- Thymic Carcinoma

## Interventions

- **DRUG:** PXD101with cisplatin+doxorubicin+cyclophosphamide

## Key facts

- **NCT ID:** NCT01100944
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03-04
- **Primary completion:** 2015-10-21
- **Final completion:** 2015-10-21
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Principal investigator left the National Institutes of Health (NIH).
- **Last updated:** 2017-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01100944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01100944, "A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01100944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*